<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35189854</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2377</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>BMC neurology</Title><ISOAbbreviation>BMC Neurol</ISOAbbreviation></Journal><ArticleTitle>Gut- and oral-dysbiosis differentially impact spinal- and bulbar-onset ALS, predicting ALS severity and potentially determining the location of disease onset.</ArticleTitle><Pagination><StartPage>62</StartPage><MedlinePgn>62</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">62</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12883-022-02586-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prior studies on the role of gut-microbiome in Amyotrophic Lateral Sclerosis (ALS) pathogenesis have yielded conflicting results. We hypothesized that gut- and oral-microbiome may differentially impact two clinically-distinct ALS subtypes (spinal-onset ALS (sALS) vs. bulbar-onset ALS (bALS), driving disagreement in the field.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">ALS patients diagnosed within 12&#xa0;months and their spouses as healthy controls (n&#x2009;=&#x2009;150 couples) were screened. For eligible sALS and bALS patients (n&#x2009;=&#x2009;36) and healthy controls (n&#x2009;=&#x2009;20),&#xa0;16S rRNA next-generation sequencing was done in fecal and saliva samples after DNA extractions to examine gut- and oral-microbiome differences. Microbial translocation to blood was measured by blood lipopolysaccharide-binding protein (LBP) and 16S rDNA levels. ALS severity was assessed by Revised ALS Functional Rating Scale (ALSFRS-R).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">sALS patients manifested significant gut-dysbiosis, primarily driven by increased&#xa0;fecal Firmicutes/Bacteroidetes-ratio (F/B-ratio). In contrast,&#xa0;bALS patients displayed significant oral-dysbiosis, primarily driven by decreased oral&#xa0;F/B-ratio.&#xa0;For sALS patients, gut-dysbiosis (a shift in fecal&#xa0;F/B-ratio), but not oral-dysbiosis, was strongly associated with greater microbial translocation to blood (r&#x2009;=&#x2009;0.8006,&#xa0;P&#x2009;&lt;&#x2009;0.0001) and more severe symptoms (r&#x2009;=&#x2009;0.9470,&#xa0;P&#x2009;&lt;&#x2009;0.0001). In contrast, for bALS patients, oral-dysbiosis (a shift in oral&#xa0;F/B-ratio), but not gut-dysbiosis, was strongly associated with greater microbial translocation to blood (r&#x2009;=&#x2009;0.9860,&#xa0;P&#x2009;&lt;&#x2009;0.0001) and greater disease severity (r&#x2009;=&#x2009;0.9842,&#xa0;P&#x2009;&lt;&#x2009;0.0001). For both ALS subtypes, greater microbial translocation was associated with more severe symptoms&#xa0;(sALS: r&#x2009;=&#x2009;0.7924, P&#x2009;&lt;&#x2009;0.0001; bALS: r&#x2009;=&#x2009;0.7496, P&#x2009;=&#x2009;0.0067).&#xa0;Importantly, both sALS and bALS patients displayed comparable oral-motor deficits with associations between oral-dysbiosis and severity of oral-motor deficits in bALS but not sALS. This suggests that oral-dysbiosis is not simply caused by oral/bulbar/respiratory symptoms but represents a pathological driver of bALS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We found increasing gut-dysbiosis with worsening symptoms in sALS patients and increasing oral-dysbiosis with worsening symptoms in bALS patients. Our findings support distinct microbial mechanisms underlying two ALS subtypes, which have been previously grouped together as a single disease. Our study suggests correcting gut-dysbiosis as a therapeutic strategy for sALS patients and correcting oral-dysbiosis as a therapeutic strategy for bALS patients.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Harper S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Scientist Training Program, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California Irvine, Irvine, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Donghwan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesiology, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Danny</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Nursing, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chocron</LastName><ForeName>E Sandra</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Seongwoo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kittrell</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murchison</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Richard E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tobon</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, South Texas Veteran Health Care System, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Carlayne E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health San Antonio, San Antonio, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pickering</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. ampickering@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barshop Institute for Longevity and Aging Studies, University of Texas Health San Antonio, San Antonio, TX, USA. ampickering@uabmc.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Medicine, University of Texas Health San Antonio, San Antonio, TX, USA. ampickering@uabmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH121928</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG061051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG065301</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AG061051, T32AG021890, T32GM008361-28, T32GM113896,</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Neurol</MedlineTA><NlmUniqueID>100968555</NlmUniqueID><ISSNLinking>1471-2377</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064806" MajorTopicYN="N">Dysbiosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Lou Gehrig&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Microbiome</Keyword></KeywordList><CoiStatement>All authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35189854</ArticleId><ArticleId IdType="pmc">PMC8862222</ArticleId><ArticleId IdType="doi">10.1186/s12883-022-02586-5</ArticleId><ArticleId IdType="pii">10.1186/s12883-022-02586-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol. 2014;10(11):661&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, Group Ps Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Moura MC, Novaes MR, Eduardo EJ, Zago YS, Freitas Rdel N, Casulari LA. Prognostic Factors in Amyotrophic Lateral Sclerosis: A Population-Based Study. PLoS One. 2015;10(10):e0141500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4627754</ArticleId><ArticleId IdType="pubmed">26517122</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila MA, Longstreth WT, Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003;60(5):813&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">12629239</ArticleId></ArticleIdList></Reference><Reference><Citation>Shellikeri S, Karthikeyan V, Martino R, Black SE, Zinman L, Keith J, et al. The neuropathological signature of bulbar-onset ALS: A systematic review. Neurosci Biobehav Rev. 2017;75:378&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5425954</ArticleId><ArticleId IdType="pubmed">28163193</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, de Leon M, Wang X, Kim HY, Lee YJ, Kim YH, et al. Relationship between Clinical Parameters and Brain Structure in Sporadic Amyotrophic Lateral Sclerosis Patients According to Onset Type: A Voxel-Based Morphometric Study. PLoS One. 2017;12(1):e0168424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240978</ArticleId><ArticleId IdType="pubmed">28095425</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WH, van den Berg LH, et al. The ALS-FTD-Q: a new screening tool for behavioral disturbances in ALS. Neurology. 2012;79(13):1377&#x2013;1383.</Citation><ArticleIdList><ArticleId IdType="pubmed">22972650</ArticleId></ArticleIdList></Reference><Reference><Citation>Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 1995;52(6):559&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">7763202</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp SE, Brown JW, Stanford JA. Time-course and characterization of orolingual motor deficits in B6SJL-Tg(SOD1-G93A)1Gur/J mice. Neuroscience. 2008;151(2):613&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2244802</ArticleId><ArticleId IdType="pubmed">18061359</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Asmakh M, Hedin L. Microbiota and the control of blood-tissue barriers. Tissue Barriers. 2015;3(3):e1039691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4574894</ArticleId><ArticleId IdType="pubmed">26451344</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke G, Stilling RM, Kennedy PJ, Stanton C, Cryan JF, Dinan TG. Minireview: Gut microbiota: the neglected endocrine organ. Mol Endocrinol. 2014;28(8):1221&#x2013;1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5414803</ArticleId><ArticleId IdType="pubmed">24892638</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20(2):145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6960010</ArticleId><ArticleId IdType="pubmed">28092661</ArticleId></ArticleIdList></Reference><Reference><Citation>Harach T, Marungruang N, Duthilleul N, Cheatham V, Mc Coy KD, Frisoni G, et al. Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. Sci Rep. 2017;7:41802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5297247</ArticleId><ArticleId IdType="pubmed">28176819</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, et al. Gut microbiome alterations in Alzheimersss disease. Sci Rep. 2017;7(1):13537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648830</ArticleId><ArticleId IdType="pubmed">29051531</ArticleId></ArticleIdList></Reference><Reference><Citation>Minter MR, Zhang C, Leone V, Ringus DL, Zhang X, Oyler-Castrillo P, et al. Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer&#x2019;s disease. Sci Rep. 2016;6:30028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4956742</ArticleId><ArticleId IdType="pubmed">27443609</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, et al. Colonic bacterial composition in Parkinson&#x2019;s disease. Mov Disord. 2015;30(10):1351&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26179554</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson&#x2019;s Disease. Cell. 2016;167(6):1469-80.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun MF, Zhu YL, Zhou ZL, Jia XB, Xu YD, Yang Q, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson&#x2019;s disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. Brain Behav Immun. 2018;70:48&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29471030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonfili L, Cecarini V, Gogoi O, Berardi S, Scarpona S, Angeletti M, et al. Gut microbiota manipulation through probiotics oral administration restores glucose homeostasis in a mouse model of Alzheimer's disease. Neurobiol Aging. 2019;87:35&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31813629</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MS, Kim Y, Choi H, Kim W, Park S, Lee D, et al. Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer&#x2019;s disease animal model. Gut. 2020;69(2):283&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">31471351</ArticleId></ArticleIdList></Reference><Reference><Citation>Mihaila D, Donegan J, Barns S, LaRocca D, Du Q, Zheng D, et al. The oral microbiome of early stage Parkinson&#x2019;s disease and its relationship with functional measures of motor and non-motor function. PLoS One. 2019;14(6):e0218252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6597068</ArticleId><ArticleId IdType="pubmed">31247001</ArticleId></ArticleIdList></Reference><Reference><Citation>Poole S, Singhrao SK, Kesavalu L, Curtis MA, Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer&#x2019;s disease brain tissue. J Alzheimers Dis. 2013;36(4):665&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">23666172</ArticleId></ArticleIdList></Reference><Reference><Citation>Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer&#x2019;s disease. Oral Microbiol Immunol. 2002;17(2):113&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11929559</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi A, Miki M, Muto A, Kubokawa K, Migita K, Higashi Y, et al. Association between oral health and the risk of lacunar infarction in Japanese adults. Gerontology. 2013;59(6):499&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">23942139</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble JM, Borrell LN, Papapanou PN, Elkind MS, Scarmeas N, Wright CB. Periodontitis is associated with cognitive impairment among older adults: analysis of NHANES-III. J Neurol Neurosurg Psychiatry. 2009;80(11):1206&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073380</ArticleId><ArticleId IdType="pubmed">19419981</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble JM, Scarmeas N, Celenti RS, Elkind MS, Wright CB, Schupf N, et al. Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer disease. PLoS One. 2014;9(12):e114959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270775</ArticleId><ArticleId IdType="pubmed">25522313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamer AR, Craig RG, Pirraglia E, Dasanayake AP, Norman RG, Boylan RJ, et al. TNF-alpha and antibodies to periodontal bacteria discriminate between Alzheimer&#x2019;s disease patients and normal subjects. J Neuroimmunol. 2009;216(1&#x2013;2):92&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783848</ArticleId><ArticleId IdType="pubmed">19767111</ArticleId></ArticleIdList></Reference><Reference><Citation>Beydoun MA, Beydoun HA, Weiss J, Hossain S, El-Hajj ZW, Zonderman AB. Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer's disease dementia in a large national survey. Mol Psychiatry. 2020;26:6038&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32366948</ArticleId></ArticleIdList></Reference><Reference><Citation>Demmer RT, Norby FL, Lakshminarayan K, Walker KA, Pankow JS, Folsom AR, et al. Periodontal disease and incident dementia: The Atherosclerosis Risk in Communities Study (ARIC) Neurology. 2020;95(12):e1660&#x2013;e1671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713724</ArticleId><ArticleId IdType="pubmed">32727837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilievski V, Zuchowska PK, Green SJ, Toth PT, Ragozzino ME, Le K, et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One. 2018;13(10):e0204941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6169940</ArticleId><ArticleId IdType="pubmed">30281647</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer&#x2019;s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv. 2019;5(1):eaau3333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357742</ArticleId><ArticleId IdType="pubmed">30746447</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572(7770):474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Yi J, Zhang YG, Zhou J, Sun J. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep. 2015;3(4):e12356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425962</ArticleId><ArticleId IdType="pubmed">25847918</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YG, Wu S, Yi J, Xia Y, Jin D, Zhou J, et al. Target Intestinal Microbiota to Alleviate Disease Progression in Amyotrophic Lateral Sclerosis. Clin Ther. 2017;39(2):322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344195</ArticleId><ArticleId IdType="pubmed">28129947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Wang X, Yang S, Meng F, Wang X, Wei H, et al. Evaluation of the Microbial Diversity in Amyotrophic Lateral Sclerosis Using High-Throughput Sequencing. Front Microbiol. 2016;7:1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028383</ArticleId><ArticleId IdType="pubmed">27703453</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, et al. The fecal microbiome of ALS patients. Neurobiol Aging. 2018;61:132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">29065369</ArticleId></ArticleIdList></Reference><Reference><Citation>Niccolai E, Di Pilato V, Nannini G, Baldi S, Russo E, Zucchi E, et al. The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity? Biomedicines. 2021;9(7):753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8301418</ArticleId><ArticleId IdType="pubmed">34209688</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012;338(6103):120&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3645302</ArticleId><ArticleId IdType="pubmed">22903521</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo X, Xia X, Tang R, Zhou J, Zhao H, Wang K. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol. 2008;47(5):367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146523</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl Environ Microbiol. 2004;70(12):7220&#x2013;7228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC535136</ArticleId><ArticleId IdType="pubmed">15574920</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W. A protocol for quantizing total bacterial 16S rDNA in plasma as a marker of microbial translocation in vivo. Cell Mol Immunol. 2018;15(10):937&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6207554</ArticleId><ArticleId IdType="pubmed">29658510</ArticleId></ArticleIdList></Reference><Reference><Citation>Lochman J, Zapletalova M, Poskerova H, Izakovicova Holla L, Borilova Linhartova P. Rapid Multiplex Real-Time PCR Method for the Detection and Quantification of Selected Cariogenic and Periodontal Bacteria. Diagnostics (Basel). 2019;10(1):8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7168300</ArticleId><ArticleId IdType="pubmed">31877891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Hung GC, Nagamine K, Li B, Tsai S, Lo SC. Development of Candida-Specific Real-Time PCR Assays for the Detection and Identification of Eight Medically Important Candida Species. Microbiol Insights. 2016;9:21&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4836890</ArticleId><ArticleId IdType="pubmed">27103821</ArticleId></ArticleIdList></Reference><Reference><Citation>Borcard D, Fo Gillet, Legendre P. Numerical ecology with R. New York: Springer; 2011.</Citation></Reference><Reference><Citation>Song SJ, Lauber C, Costello EK, Lozupone CA, Humphrey G, Berg-Lyons D, et al. Cohabiting family members share microbiota with one another and with their dogs. Elife. 2013;2:e00458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3628085</ArticleId><ArticleId IdType="pubmed">23599893</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BR, Shin J, Guevarra R, Lee JH, Kim DW, Seol KH, et al. Deciphering Diversity Indices for a Better Understanding of Microbial Communities. J Microbiol Biotechnol. 2017;27(12):2089&#x2013;2093.</Citation><ArticleIdList><ArticleId IdType="pubmed">29032640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol. 2009;9:123.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702274</ArticleId><ArticleId IdType="pubmed">19508720</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilg H, Kaser A. Gut microbiome, obesity, and metabolic dysfunction. J Clin Invest. 2011;121(6):2126&#x2013;2132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104783</ArticleId><ArticleId IdType="pubmed">21633181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, et al. Gut Microbiota is Altered in Patients with Alzheimer&#x2019;s Disease. J Alzheimers Dis. 2018;63(4):1337&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">29758946</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanguinetti E, Collado MC, Marrachelli VG, Monleon D, Selma-Royo M, Pardo-Tendero MM, et al. Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet. Sci Rep. 2018;8(1):4907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5861049</ArticleId><ArticleId IdType="pubmed">29559675</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Burmann J, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson&#x2019;s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">27591074</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Qian Y, Xu S, Song Y, Xiao Q. Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson&#x2019;s Disease. Front Aging Neurosci. 2017;9:441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5766661</ArticleId><ArticleId IdType="pubmed">29358918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira PAB, Aho VTE, Paulin L, Pekkonen E, Auvinen P, Scheperjans F. Oral and nasal microbiota in Parkinson&#x2019;s disease. Parkinsonism Relat Disord. 2017;38:61&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28259623</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson&#x2019;s disease and clinical phenotype. Mov Disord. 2015;30(3):350&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25476529</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, et al. Altered microbiomes distinguish Alzheimer&#x2019;s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun. 2019;80:633&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31063846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67(46):1285&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mogna L, De Marchi F, Amoruso A, Pane M, Aloisio I, et al. Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies. J Clin Gastroenterol. 2018;52 Suppl 1, Proceedings from the 9th Probiotics, Prebiotics and New Foods, Nutraceuticals and Botanicals for Nutrition &amp; Human and Microbiota Health Meeting, held in Rome, Italy from September 10 to 12, 2017:S68&#x2013;S70.</Citation><ArticleIdList><ArticleId IdType="pubmed">29782468</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Rocha ML, Ferreira J, Evangelista T, Coelho M, de Carvalho M. Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis. J Neurol. 2008;255(4):545&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">18283399</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L, Shi W. Salivary biomarkers for caries risk assessment. J Calif Dent Assoc. 2013;41(2):107&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3825179</ArticleId><ArticleId IdType="pubmed">23505756</ArticleId></ArticleIdList></Reference><Reference><Citation>Baughan LW, Robertello FJ, Sarrett DC, Denny PA, Denny PC. Salivary mucin as related to oral Streptococcus mutans in elderly people. Oral Microbiol Immunol. 2000;15(1):10&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">11155158</ArticleId></ArticleIdList></Reference><Reference><Citation>van Houte J. Microbiological predictors of caries risk. Adv Dent Res. 1993;7(2):87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">8260016</ArticleId></ArticleIdList></Reference><Reference><Citation>Loesche WJ. Role of Streptococcus mutans in human dental decay. Microbiol Rev. 1986;50(4):353&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC373078</ArticleId><ArticleId IdType="pubmed">3540569</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler B, Bjarnason S. Mutans streptococci, lactobacilli and caries prevalence in 15 to 16-year olds in Goteborg. Part II Swed Dent J. 1992;16(6):253&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1481133</ArticleId></ArticleIdList></Reference><Reference><Citation>Klock B, Svanberg M, Petersson LG. Dental caries, mutans streptococci, lactobacilli, and saliva secretion rate in adults. Community Dent Oral Epidemiol. 1990;18(5):249&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">2249407</ArticleId></ArticleIdList></Reference><Reference><Citation>Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med. 2011;3(9):559&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3265717</ArticleId><ArticleId IdType="pubmed">21735552</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehle JR, Jr, Leng X, Kitzman DW, Nicklas BJ, Kritchevsky SB, High KP. Lipopolysaccharide-binding protein, a surrogate marker of microbial translocation, is associated with physical function in healthy older adults. J Gerontol A Biol Sci Med Sci. 2012;67(11):1212&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636679</ArticleId><ArticleId IdType="pubmed">22960476</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y, Yang X, Xu S, Wu C, Qin N, Chen SD, et al. Detection of Microbial 16S rRNA Gene in the Blood of Patients With Parkinson&#x2019;s Disease. Front Aging Neurosci. 2018;10:156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5976788</ArticleId><ArticleId IdType="pubmed">29881345</ArticleId></ArticleIdList></Reference><Reference><Citation>Fardini Y, Wang X, Temoin S, Nithianantham S, Lee D, Shoham M, et al. Fusobacterium nucleatum adhesin FadA binds vascular endothelial cadherin and alters endothelial integrity. Mol Microbiol. 2011;82(6):1468&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237733</ArticleId><ArticleId IdType="pubmed">22040113</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowin J, Xia Y, Jung B, Sun J. Gut inflammation and dysbiosis in human motor neuron disease. Physiol Rep. 2017;5(18):e13443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617930</ArticleId><ArticleId IdType="pubmed">28947596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngo ST, Restuadi R, McCrae AF, Van Eijk RP, Garton F, Henderson RD, et al. Progression and survival of patients with motor neuron disease relative to their fecal microbiota. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(7&#x2013;8):549&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pubmed">32643435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan H, Diao H, Xiao Y, Li W, Yu B, He J, et al. Gut microbiota can transfer fiber characteristics and lipid metabolic profiles of skeletal muscle from pigs to germ-free mice. Sci Rep. 2016;6:31786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4992887</ArticleId><ArticleId IdType="pubmed">27545196</ArticleId></ArticleIdList></Reference><Reference><Citation>Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979&#x2013;984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1764762</ArticleId><ArticleId IdType="pubmed">17210919</ArticleId></ArticleIdList></Reference><Reference><Citation>Manickam R, Oh HYP, Tan CK, Paramalingam E, Wahli W. Metronidazole Causes Skeletal Muscle Atrophy and Modulates Muscle Chronometabolism. Int J Mol Sci. 2018;19(8):2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6121908</ArticleId><ArticleId IdType="pubmed">30115857</ArticleId></ArticleIdList></Reference><Reference><Citation>Palamiuc L, Schlagowski A, Ngo ST, Vernay A, Dirrig-Grosch S, Henriques A, et al. A metabolic switch toward lipid use in glycolytic muscle is an early pathologic event in a mouse model of amyotrophic lateral sclerosis. EMBO Mol Med. 2015;7(5):526&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4492815</ArticleId><ArticleId IdType="pubmed">25820275</ArticleId></ArticleIdList></Reference><Reference><Citation>Smittkamp SE, Morris JK, Bomhoff GL, Chertoff ME, Geiger PC, Stanford JA. SOD1-G93A mice exhibit muscle-fiber-type-specific decreases in glucose uptake in the absence of whole-body changes in metabolism. Neurodegener Dis. 2014;13(1):29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3970434</ArticleId><ArticleId IdType="pubmed">24021858</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu C, Cao J, Liu K, Tan B, Zhu C, Li K, et al. Crohn&#x2019;s Disease Complicated With Extensive Thrombosis of Limbs and Mesenteric Arteries: A Case Report and Literature Review. Ann Vasc Surg. 2019;58(382):e15&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30802583</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoluzi OA, Crispino P, Rivera M, Iacopini F, Palladini D, Consolazio A, et al. Skeletal muscle disorders associated with inflammatory bowel diseases: occurrence of myositis in a patient with ulcerative colitis and Hashimoto&#x2019;s thyroiditis&#x2013;case report and review of the literature. Int J Colorectal Dis. 2006;21(5):473&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16205931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1773911</ArticleId><ArticleId IdType="pubmed">14684564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaltman C, Braulio VB, Outeiral R, Nunes T, de Castro CL. Lower extremity mobility limitation and impaired muscle function in women with ulcerative colitis. J Crohns Colitis. 2014;8(6):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">24315794</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104(9):1223&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC409820</ArticleId><ArticleId IdType="pubmed">10545521</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, et al. Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer. JAMA Oncol. 2018;4(3):358&#x2013;365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885828</ArticleId><ArticleId IdType="pubmed">29327043</ArticleId></ArticleIdList></Reference><Reference><Citation>Burleigh MC, Liddle L, Monaghan C, Muggeridge DJ, Sculthorpe N, Butcher JP, et al. Salivary nitrite production is elevated in individuals with a higher abundance of oral nitrate-reducing bacteria. Free Radic Biol Med. 2018;120:80&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">29550328</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez A, Schiffer TA, Ivarsson N, Cheng AJ, Bruton JD, Lundberg JO, et al. Dietary nitrate increases tetanic [Ca2+]i and contractile force in mouse fast-twitch muscle. J Physiol. 2012;590(15):3575&#x2013;3583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3547271</ArticleId><ArticleId IdType="pubmed">22687611</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Martin LJ. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. Hum Mol Genet. 2010;19(11):2284&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865380</ArticleId><ArticleId IdType="pubmed">20223753</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis. Brain Pathol. 2016;26(2):227&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pierro F, Zanvit A, Nobili P, Risso P, Fornaini C. Cariogram outcome after 90 days of oral treatment with Streptococcus salivarius M18 in children at high risk for dental caries: results of a randomized, controlled study. Clin Cosmet Investig Dent. 2015;7:107&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4598214</ArticleId><ArticleId IdType="pubmed">26491371</ArticleId></ArticleIdList></Reference><Reference><Citation>Vientos-Plotts AI, Ericsson AC, Rindt H, Reinero CR. Oral Probiotics Alter Healthy Feline Respiratory Microbiota. Front Microbiol. 2017;8:1287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5504723</ArticleId><ArticleId IdType="pubmed">28744273</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>